• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Interactio

  2026-06-11

  The reference study uncovers how naturally occurring angiotensin peptides, including fragments related to Angiotensin 1/2 (2-7), significantly enhance the binding of the SARS-CoV-2 spike protein to host cell receptors, particularly AXL. This mechanistic insight broadens our understanding of the renin-angiotensin system's cross-talk with viral entry pathways, informing both cardiovascular and infectious disease research.

• Dabigatran Etexilate: Advancing Oral Anticoagulation Researc

  2026-06-10

  This article reviews the seminal clinical analysis of dabigatran etexilate as a novel oral direct thrombin inhibitor, emphasizing its pharmacological innovation and impact on stroke and venous thromboembolism prevention. The referenced study demonstrates how dabigatran addresses limitations of traditional anticoagulants, offering researchers a model for more predictable and accessible anticoagulation strategies.

• Troxerutin Attenuates Diabetic Cognitive Dysfunction via TRP

  2026-06-10

  This study demonstrates that troxerutin improves diabetic cognitive dysfunction by inhibiting TRPM7-mediated mitochondrial fission through the CaN/Drp1ser637 pathway. The findings highlight TRPM7 as a mechanistic target, offering insight into mitochondrial dynamics in diabetic neurodegeneration and suggesting new research avenues for endothelium-dependent vasodilator studies.

• A-769662 and the Evolving Paradigm of AMPK Activation in Ene

  2026-06-09

  Explore how A-769662, a potent AMPK activator, is redefining experimental strategies in energy metabolism and autophagy research. This in-depth analysis connects new mechanistic insights to practical assay design with unique guidance for advanced metabolic workflows.

• Phosphoproteomic Adaptation to Chronic Cabozantinib in RCC C

  2026-06-09

  This study systematically explores how acute versus chronic exposure to Cabozantinib (XL184) remodels the phosphoproteome of renal cell carcinoma (RCC) cells, using quantitative phosphoproteomics. The findings reveal distinct, timescale-dependent reprogramming of kinase networks, with implications for understanding adaptation, motility changes, and resistance mechanisms under sustained multi-kinase inhibition.

• Engineering Ternary RNA Nanoparticles: Inside-Out Structure–

  2026-06-08

  This study pioneers the rational design of ternary polyelectrolyte nanoparticles (TNPs) for RNA delivery by elucidating how polyanion chemistry governs particle stability, structure, and biological function. The findings provide a framework for engineering pH-responsive, protein-resistant RNA carriers, offering new perspectives for nucleic acid delivery technologies.

• DiscoveryProbe™ Protease Inhibitor Library: Precision Tools

  2026-06-08

  Explore how the DiscoveryProbe Protease Inhibitor Library empowers precision, high-throughput investigation of protease inhibition, with a focus on mechanistic assay optimization and translational research. Distinct from previous articles, this analysis integrates reference breakthroughs in autoprocessing and resistance assessment.

• Hypoxia-Driven Immunometabolism: Mechanisms and Redox Analys

  2026-06-07

  This review deciphers how hypoxia and immune metabolism orchestrate the tumor microenvironment, driving immunosuppression and metabolic reprogramming. The study provides a mechanistic framework for understanding how oxygen deprivation and metabolic adaptation shape tumor progression and identifies emerging strategies for targeted therapy.

• Thiamet G: Advancing O-GlcNAcase Inhibitor Research Workflow

  2026-06-06

  Thiamet G unlocks rapid, precise control over O-GlcNAcylation, enabling next-generation studies in bone formation, neurodegeneration, and cancer sensitization. This guide delivers actionable workflows and troubleshooting strategies to maximize the utility of this potent O-GlcNAcase inhibitor in cellular and animal models.

• NBC19: A Potent NLRP3 Inflammasome Inhibitor for Inflammatio

  2026-06-05

  NBC19 delivers nanomolar precision for dissecting NLRP3 inflammasome signaling, empowering next-generation inflammation research. Its robust inhibition of IL-1β release across both Nigericin- and ATP-induced activation models unlocks advanced protocol flexibility and reproducibility.

• CB-5083: Precision p97 Inhibitor Workflows in Cancer Researc

  2026-06-05

  CB-5083, a selective and orally bioavailable p97 inhibitor, empowers oncology researchers to dissect protein homeostasis disruption and drive tumor apoptosis with nanomolar precision. This article demystifies advanced experimental workflows, troubleshooting strategies, and highlights cross-domain insights into genome stability and aging.

• Netrin-1 Regulates Adipogenesis via PPARγ and Wnt/β-Catenin

  2026-06-04

  This study uncovers how adipose-derived Netrin-1 impairs high-fat-diet-induced adipogenesis by modulating PPARγ inhibition and Wnt/β-catenin activation. The findings enhance our understanding of adipose tissue remodeling in obesity and type 2 diabetes, identifying Netrin-1 as a potential therapeutic target for metabolic disorders.

• Polybrene (Hexadimethrine Bromide): Optimizing Viral Transdu

  2026-06-04

  Polybrene (Hexadimethrine Bromide) 10 mg/mL elevates gene delivery efficiency in even the most challenging cell lines, acting as a viral attachment facilitator and lipid-mediated DNA transfection enhancer. This guide details practical protocol enhancements, troubleshooting strategies, and evidence-based optimization for advanced genome engineering workflows.

• Angiotensin 1/2 (2-7): Strategic Advances for Translational

  2026-06-03

  This thought-leadership article explores the mechanistic, experimental, and translational significance of Angiotensin 1/2 (2-7) peptide, offering strategic guidance for researchers in cardiovascular and infectious disease domains. Integrating recent peer-reviewed findings and advanced product intelligence from APExBIO, it provides actionable insights for optimizing research workflows, bridging cross-domain applications, and anticipating future directions in blood pressure and viral pathogenesis studies.

• Urolithin A: Mechanisms, Evidence, and Workflow Integration

  2026-06-03

  Urolithin A (3,8-dihydroxy-6H-benzo[c]chromen-6-one) is a gut microbiota-derived metabolite that promotes mitochondrial quality control via mitophagy. Evidence supports its role in enhancing mitochondrial biogenesis and modulating skeletal muscle gene expression, with additional anti-inflammatory and antioxidant effects. The compound's stability profile and high purity make it suitable for advanced mitochondrial research.

16878 records 2/1126 page Previous Next 12345 下5页 Last page